Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2024 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen. And welcome to the Amicus Therapeutics Second Quarter 2024 Financial Results Conference Call and Webcast.
Amicus Therapeutics Inc. (FOLD)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Perceptive Advisors Joseph Edelman | 28,057,456 | $278,329,964 | 6.7% | |
| 2. | VenBio Select Advisor Kurt Von Emster | 27,400,000 | $271,808,000 | 3.62% | |
| 3. | Redmile Group Jeremy Green | 10,595,089 | $105,103,283 | -21% | 6.35% |
| 4. | Palo Alto Investors William Leland Edwards | 9,029,843 | $89,576,043 | -4% | 10.37% |
| 5. | Citadel Investment Group Ken Griffin | 3,016,896 | $29,927,608 | +124% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.49 | 1,500 | Director | 65,082 | 2021-11-01 | Filing | |
| $9.56 | 1,500 | Director | 63,582 | 2021-10-01 | Filing | |
| $11.41 | 1,500 | Director | 62,082 | 2021-09-01 | Filing | |
| $9.28 | 1,500 | Director | 60,582 | 2021-08-02 | Filing | |
| $9.24 | 1,500 | Director | 47,467 | 2021-06-01 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.71 | 7,500 | 886,654 | 2024-09-03 | Filing | ||
| $10.34 | 7,500 | 886,654 | 2024-08-01 | Filing | ||
| $10.00 | 6,100 | 886,654 | 2024-07-05 | Filing | ||
| $10.00 | 1,400 | 886,654 | 2024-07-01 | Filing | ||
| $10.00 | 7,500 | 886,654 | 2024-06-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 28,492,486 | $404,308,376 | 0% | |
| 2. | 22,988,139 | $326,201,690 | 0% | |
| 3. | 17,848,531 | $253,270,655 | 0.02% | |
| 4. | 15,190,024 | $215,546,442 | 0.04% | |
| 5. | 13,327,897 | $189,122,871 | 0.01% |
News See All
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call Transcript
Amicus Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.15985 EPS, expectations were $-0.06. Amicus Therapeutics, Inc.
13 Best Biotech Stocks To Buy Under $20
In this article, we're going to take a look at 13 best biotech stocks to buy under $20.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2023 Earnings Call Transcript
Operator: Good morning ladies and gentlemen and welcome to the Amicus Therapeutics' Full Year 2023 Financial Results Conference Call and Webcast.
20 Fastest Growing Biotech Companies in the US
In this article, we will be taking a look at the 20 fastest growing biotech companies in the US.
15 Best Growth Stocks to Buy Under $25
The markets have rallied for the better part of the year at the back of the US Federal Reserve, hiking interest rates to 22-year highs.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen and welcome to the Amicus Therapeutics Third Quarter 2023 Financial Results Conference Call and webcast.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q2 2023 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen and welcome to the Amicus Therapeutics Second Quarter 2023 Financial Results Conference Call and webcast.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2023 Earnings Call Transcript
Operator: Good morning ladies and gentlemen and welcome to the Amicus Therapeutics first quarter 2023 financial results conference call and webcast.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q4 2022 Earnings Call Transcript
Operator: Good morning ladies and gentlemen and welcome to the Amicus Therapeutics Full Year 2022 financial results conference call and webcast.
Billionaire Hedge Funds
